We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

The FDA has granted Fast Track designation to rezpegaldesleukin for the treatment of moderate to severe atopic dermatitis.

Patients with mild atopic dermatitis who reported nighttime scratching experienced relief when they used an artificial intelligence (AI)-powered wearable sensor that delivered haptic feedback on sleep ...

The production of isocyanate compounds from the environment may explain the increasing prevalence of atopic dermatitis, according to a speaker at Masters of Pediatric Dermatology. “We understand that ...

Q4 2024 Earnings Call Transcript February 10, 2025 Operator: Greetings, and welcome to the Incyte Fourth Quarter 2024 and ...

Aclaris' stock has dropped nearly 70% since September 2023, reflecting its history of failures and dissipations. Explore more ...

Despite the failure of an eczema trial in December, Q32 Bio is sticking with bempikibart. But a phase 2-stage complement inhibitor and a number of the biotech’s “valued colleagues” won’t be so lucky.

Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...

More information about the 2025 AAAAI / WAO Joint Congress can be accessed here.

Q4 2024 total revenues reached $1.2 billion, with $1 billion in product revenues. Jakafi's Q4 net revenue increased 11% year-over-year to $773 million, while Opzelura's Q4 revenue grew 48% to $162 ...